SeqLL Inc is a biotechnology company that specializes in developing innovative sequencing technologies and solutions. The company was founded in 2010 and is headquartered in Woburn, Massachusetts, USA. SeqLL's primary focus is on advancing next-generation sequencing (NGS) technologies to enable researchers and scientists to gain valuable insights into genomics and transcriptomics.
SeqLL is committed to providing high-quality, reliable, and cost-effective sequencing solutions to its customers. Their technology platform is designed to support a wide range of applications in fields such as biomedical research, pharmaceuticals, diagnostics, and agriculture. By offering advanced sequencing capabilities, SeqLL aims to accelerate scientific discovery and contribute to various areas of life sciences research.
The company's proprietary Long-Read Sequencing (LRS) technology distinguishes itself by delivering long read lengths, enabling researchers to access more comprehensive genomic information, including full-length transcripts and challenging genomic regions. The technology also provides high sequencing accuracy, which is critical for applications such as variant detection and gene expression profiling.
While SeqLL is primarily known for its research-grade sequencing solutions, the company also collaborates with partners and customers to develop customized sequencing applications tailored to specific research needs. This approach helps researchers address complex scientific questions and opens up opportunities for novel discoveries.
Given the rapidly evolving field of genomics and NGS technologies, SeqLL continues to invest in research and development to advance its sequencing platform and offer cutting-edge solutions to the scientific community. The company's dedication to innovation and commitment to customer satisfaction positions it as a significant player in the genomics and sequencing industry.